RecruitingPhase 3NCT06626503

Evaluation of Analgesia for Spine Fusion Elective Surgery in Children

Prospective Randomized Evaluation of Analgesia for Spine Fusion Elective Surgery in Children (PRECISE Spine Trial)


Sponsor

Senthil Sadhasivam

Enrollment

500 participants

Start Date

Oct 30, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The multicenter PRECISE Analgesia (Prospective Randomized Evaluation of Analgesia for Idiopathic Scoliosis Spine Fusion Elective Surgery in Children) trials will a) implement and investigate the efficacy and safety of multidose methadone-based standardized enhanced recovery after surgery (ERAS) protocol, and b) develop personalized ERAS protocols including precision methadone and oxycodone dosing1,2 and c) personalized analgesia for the safe and effective opioid-sparing management of surgical pain after posterior spine fusion (PSF) in children.


Eligibility

Min Age: 10 YearsMax Age: 18 Years

Inclusion Criteria4

  • Participants aged 10-\<18yrs for PSF trial
  • ASA physical status 1\&2
  • Undergoing PSF for idiopathic scoliosis
  • Participant or legal guardian can speak and read English or Spanish

Exclusion Criteria7

  • Pregnant patients
  • Methadone allergy
  • Preoperative prolonged QTc more than 460 msec (-30 days to 0 day)
  • Subjects undergoing concomitant treatment with known cytochrome P450 inhibitors included in methadone labeling (i.e. macrolides \[e.g., erythromycin\], azole-antifungal agents \[e.g., ketoconazole, voriconazole\], protease inhibitors \[e.g., ritonavir\], fluconazole, SSRIs \[e.g., sertraline, fluvoxamine\])
  • Preoperative opioid use within 30-days before surgery
  • History of severe sleep apnea (have a sleep study with an AHI index score more than 10 or clinical signs of sleep disordered breathing - snoring, daytime drowsiness)
  • Significant liver, kidney, neurological disease, developmental delay, or any other co-existing medical condition per discretion of the clinical investigator.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethadone based ERAS

Methadone intervention includes intraoperative intravenous methadone (1st dose: 0.1 mg/kg up to a maximum of 5 mg before incision; 2nd dose: 0.05 mg/kg up to a maximum of 2.5 mg 4 hours after 1st dose) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.

DRUGNon-methadone based group

Non-methadone intervention includes standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards. Postoperative pain medication is recommended when reported pain level is considered moderate or higher (≥4 on NRS and FLACC).


Locations(1)

UPMC Children's Hospital

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06626503


Related Trials